1. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors 
Mohamed Shanavas, Uday Popat, Laura C. Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, Roni Tamari, Murat O. Arcasoy, James Davies, Usama Gergis, Oluchi C. Ukaegbu, Rammurti T. Kamble, John M. Storring, Navneet S. Majhail, Rizwan Romee, Srdan Verstovsek, Antonio Pagliuca, Sumithira Vasu, Brenda Ernst, Eshetu G. Atenafu, Ahmad Hanif, Richard Champlin, Paremeswaran Hari, Vikas Gupta 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages (March 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Allogeneic HCT outcomes in MF patients with prior exposure to JAK1/2 inhibitors. (A) Probability of OS, cumulative incidence of NRM, and cumulative incidence of relapse/progression (CIR). (B) Cumulative incidence of neutrophil count ≥.5 × 109/L and platelet count ≥20 × 109/L. (C) Cumulative incidence of acute GVHD. (D) Cumulative incidence of chronic GVHD.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Allogeneic HCT outcomes by response to prior JAK1/2 inhibitor therapy. Group A: patients who experienced clinical improvement with JAK1/2 inhibitors, Group E: patients who developed leukemic transformation while on JAK1/2 inhibitor therapy, and Group BCD: combined group of others. (A) Probability of OS, (B) cumulative incidence of NRM, and (C) cumulative incidence of relapse/progression.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions